Shares of Incyte Corporation (INCY) Sees Large Inflow of Net Money Flow

Incyte Corporation (INCY) stock had a bullish inflow of $9.29 million worth of trades on uptick and an outflow of $7.85 million in downticks on Friday. The total uptick to downtick ratio stood at 1.18. The net money flow into the stock was $1.44 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $1.44 million. $1.44 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. However, Incyte Corporation (INCY) stock traded down $0.87 , and reached $86.92, a drop of -0.99% over the previous day. On a weekly basis, the stock is 3.69%, over the previous weeks close.


Incyte Corporation (INCY) : The highest level Incyte Corporation (INCY) is projected to reach is $135 for the short term and the lowest estimate is at $76. The consolidated price target from 10 rating analysts who initiate coverage on the stock is $93.9 and the possibility the share price can swing is $16.31.

Incyte Corporation (NASDAQ:INCY): On Fridays trading session , Opening price of the stock was $88.47 with an intraday high of $88.99. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $86.37. However, the stock managed to close at $86.41, a loss of 1.57% for the day. On the previous day, the stock had closed at $87.79. The total traded volume of the day was 642,725 shares.

In a related news, Swain Paula J, officer (EVP, Human Resources) of Incyte Corp, unloaded 13,531 shares at an average price of $76.96 on January 15, 2016. The total amount of the transaction was worth $1,041,346, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.